TY  - JOUR
AU  - Trautwein, Nils Florian
AU  - Schwenck, Johannes
AU  - Jacoby, Johann
AU  - Reischl, Gerald
AU  - Fiz, Francesco
AU  - Zender, Lars
AU  - Dittmann, Helmut
AU  - Hinterleitner, Martina
AU  - la Fougère, Christian
TI  - Long-term prognostic factors for PRRT in neuroendocrine tumors.
JO  - Frontiers in medicine
VL  - 10
SN  - 2296-858X
CY  - Lausanne
PB  - Frontiers Media
M1  - DKFZ-2023-01280
SP  - 1169970
PY  - 2023
AB  - Peptide receptor radionuclide therapy (PRRT) is an effective and well-tolerated treatment option for patients with neuroendocrine tumors (NETs) that prolongs progression-free survival (PFS). However, the limited overall survival (OS) rates in the prospective phase III study (NETTER1) highlighted the need to identify patient-specific long-term prognostic markers to avoid unnecessary side effects and enable better treatment stratification. Therefore, we retrospectively analyzed prognostic risk factors in NET patients treated with PRRT.A total of 62 NET patients (G1: 33.9
KW  - 177Lu (Other)
KW  - DOTA-TATE (Other)
KW  - Ga-HA-DOTATATE (Other)
KW  - molecular tumor volume (Other)
KW  - neuroendocrine tumor (NET) (Other)
KW  - peptide receptor radionuclide therapy (PRRT) (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37359009
C2  - pmc:PMC10288842
DO  - DOI:10.3389/fmed.2023.1169970
UR  - https://inrepo02.dkfz.de/record/277115
ER  -